Wilms' Tumor 1 (WT1) Peptide Immunotherapy for Gynecological Malignancy
- SATOSHI OHNO1,2,3,
- SATORU KYO3,
- SUBARU MYOJO3,
- SATOSHI DOHI3,
- JUNKO ISHIZAKI4,
- KEN-ICHI MIYAMOTO5,
- SATOSHI MORITA6,
- JUN-ICHI SAKAMOTO7,
- TAKAYUKI ENOMOTO8,
- TADASHI KIMURA8,
- YOSHIHIRO OKA9,
- AKIHIRO TSUBOI10,
- HARUO SUGIYAMA11 and
- MASAKI INOUE3
- 1International Research and Educational Institute for Integrated Medical Sciences (IREIIMS) and
- 2Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo
- 3Department of Obstetrics and Gynecology, Kanazawa University, Graduate School of Medical Science, Ishikawa
- 4Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa
- 5Department of Pharmacy, Kanazawa University Hospital, Ishikawa
- 6Department of Biostatistics and Epidemiology, Yokohama City University Medical Center, Kanagawa
- 7Medical Administration Course of Master's Degree Program, Nagoya University, Aichi
- 8Department of Obstetrics and Gynecology, Osaka University, Graduate School of Medicine, Osaka, Japan
- 9Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University, Graduate School of Medicine, Osaka, Japan
- 10Department of Cancer Immunotherapy, Osaka University, Graduate School of Medicine, Osaka, Japan
- 11Department of Functional Diagnostic Science, Osaka University, Graduate School of Medicine, Osaka, Japan
- Correspondence to: Satoshi Ohno, International Research and Educational Institute for Integrated Medical Sciences (IREIIMS), Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. Tel: +81 333538111 ext.24068, Fax: +81 333523088, e-mail: satoshi.ohno55{at}gmail.com
Abstract
Background: The object of this study was to investigate the safety and clinical response of immunotherapy targeting the WT1 (Wilms' tumor 1) gene product in patients with gynecological cancer. Patients and Methods: Twelve patients with WT1/human leukocyte antigen (HLA)-A*2402-positive gynecological cancer were included in a Phase II clinical trial of WT1 vaccine therapy. In all the patients, the tumors were resistant to standard therapy. The patients received intradermal injections of a HLA-A*2402-restricted, modified 9-mer WT1 peptide every week for 12 weeks. Tumor size, which was measured by computed tomography (CT), was determined every 4 weeks. The responses were analyzed according to Response Evaluation Criteria in Solid Tumors (RECIST). Results: The protocol was well tolerated; only local erythema occurred at the WT1 vaccine injection site. The clinical responses were as follows: stable disease (SD) in 3 patients and progressive disease (PD) in 9 patients. No patients had a complete (CR) or partial response (PR). The disease control rate was 25.0%. Conclusion: Although a small, uncontrolled, nonrandomized trial, this study showed that WT1 vaccine therapy for patients with gynecological cancer was safe and produced a clinical response.
- Received June 24, 2009.
- Revision received October 8, 2009.
- Accepted October 13, 2009.
- Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
